CAS: 73573-88-3; (1S,7S,8S,8Ar)-8-(2-((2R,4R)-4-Hydroxy-6-Oxotetrahydro-2H-Pyran-2-yl)Ethyl)-7-Methyl-1,2,3,7,8,8A-Hexahydronaphthalen-1-Yl (S)-2-Methylbutanoate

上下游产品

(S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-[2-((2R,4R)-4,6-dihydroxy-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester (S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-diphenyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester (S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester (S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-[2-((2R,4R,6S)-4,6-dihydroxy-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl esteracetone tert-butyl alcoholtert-butyl alcohol 6-desmethylmonacolin J *,5R*),6α>>-5-oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-4-methyl-2-cyclohexen-1-one4R-4α(4R*,5R*),6α-5-2-6-2-(1,1-dimethylethyl)diphenylsilyloxyethyl-2,2-dimethyl-1,3-dioxan-4-ylethyl-4-methyl-2-cyclohexen-1-one

[(1S,7S,8S,8Ar)-8-[2-[(2R,4R)-4,6-Dihydroxyoxan-2-Yl]Ethyl]-7-Methyl-1,2,3,7,8,8A-Hexahydronaphthalen-1-Yl] (2S)-2-Methylbutanoate置于celite,Silver Carbonate体系中,用 甲苯 作为反应溶剂,化学反应 2.0H,以61%的收率获得产物美伐他汀
参考文献:(+)-Compactin 和 (+)-Mevinolin 的全合成.基于使用特殊钛试剂进行二羰基偶联的一般策略
标题:(+)-Compactin 和 (+)-Mevinolin 的全合成.基于使用特殊钛试剂进行二羰基偶联的一般策略
摘要:描述了一种用于立体控制合成低胆固醇化合物 (+)-Compactin(+)-Mevinolin 的策略
DOI:10.1021/ja00164A024

专利信息

专利号:WO-2023041627-A1
优先权日:2021-09-15
标 题 :Cleavage and synthesis of hydrogen-containing gas by means of dielectric barrier discharge
发明人：HANKE JENS; KNIST SASCHA
权利人:Synreform GmbH
摘要:The invention relates to a plasma device for the cleavage and synthesis of hydrogen-containing gas by means of dielectric barrier discharge, comprising: - a rod-type potential electrode; - a tube made of dielectric material, in particular a glass tube, more particularly a quartz glass tube, disposed around the potential electrode; - a catalyst, which is disposed in an interior of the tube; - a gas supply line, which is connected to the interior of the tube; - a gas discharge line, which is connected to the interior of the tube; - a counter electrode, which is disposed at least partly around the outside of the tube; - an active cooling means; and - a generator, which is connected to the potential electrode; wherein the generator has a predefined output impedance and is connected to the potential electrode by means of a matching network for impedance matching.

专利号:US-4739073-A
优先权日:1983-11-04
标题:Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
发明人：KATHAWALA FAIZULLA G
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Compounds of the formula wherein one of R and Ro is and the other is primary or secondary C1-6alkyl not containing an asymmetric carbon atom, C3-6cycloalkyl or phenyl(CH2)m-, wherein R4 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5a is hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R5 and R5a must be hydrogen when R4 is hydrogen, R5a must be hydrogen when R5 is hydrogen, not more than one of R4 and R5 is trifluoromethyl, not more than one of R4 and R5 is phenoxy, and not more than one of R4 and R5 is benzyloxy, R2 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C3-6cycloalkyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R3 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R3 must be hydrogen when R2 is hydrogen, not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, and not more than one of R2 and R3 is benzyloxy, X is -(CH2)n- or -CH=CH-, wherein n is 0, 1, 2 or 3, and Z is wherein R6 is hydrogen or C1-3alkyl, and R7 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, benzyl or M, wherein M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

专利号:US-4973704-A
优先权日:1985-10-25
标题 :Pyrrolyl intermediates in the synthesis of pyrrole analogs of mevalonolactone and derivatives thereof
发明人：WAREING JAMES R
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Compounds of the formula wherein R1 is C1-6alkyl not containing an asymmetric carbon atom, C3-7cycloalkyl or wherein R5, R6 and R7 are as defined below, R2 is C1-6alkyl not containing an asymmetric carbon atom, C3-7cycloalkyl or wherein R8, R9 and R10 are as defined below, R3 is hydrogen, C1-6alkyl not containing an asymmetric carbon atom, C3-7cycloalkyl or wherein R11, R12 and R13 are as defined below, R4 is hydrogen, C1-6alkyl not containing an asymmetric carbon atom, C3-7cycloalkyl or wherein R14, R15 and R16 are as defined below, X is -(CH2)m-, -CH=CH-, -CH=CH-CH2-or -CH2-CH=CH-, wherein m is 0, 1, 2 or 3, and Z is wherein R17 is hydrogen or C1-3alkyl, and R18 is hydrogen, R19 or M, wherein R19 is a physiologically acceptable ester group, and M is a pharmaceutically acceptable cation, wherein each of R5, R8, R11 and R14 is independently hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, bromo, phenyl, phenoxy or benzyloxy, each of R6, R9, R12 and R15 is independently hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, bromo, phenoxy or benzyloxy, and each of R7, R10, R13 and R16 is independently hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, with the provisos that not more than one substituent on each of Rings A, B, C and D independently is trifluoromethyl, not more than one substituent on each of Rings A, B, C and D independently is phenoxy, and not more than one substituent on each of Rings A, B, C and D independently is benzyloxy, with the provisos that (i) the -X-Z group is in the 2- or 3-position of the pyrrole ring, (ii) the -X-Z group is ortho to both R1 and R2 and (iii) R3 is ortho to R2, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

专利号:US-2002022022-A1
优先权日:2000-05-19
标题 :Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors
发明人：SHI YI; ZALEWSKI ANDREW
摘要:The present invention is directed to a method for the prophylactic and therapeutic treatment of diseases or disorders associated with the abnormal proliferation and extracellular matrix synthesis of smooth muscle cells (SMC) and fibroblasts due to activation of NAD(P)H and/or increased ROS generation. The method involves the administration of an NAD(P)H oxidase inhibitor(s) and/or antioxidant(s) to a mammal in an amount sufficient to treat the disease or disorder prophylactically or therapeutically. The NAD(P)H oxidase inhibitor inhibits the synthesis or translocation of NAD(P)H subunits, thereby blocking the generation of intracellular reactive oxygen species (ROS) and thus the proliferation and extracellular matrix synthesis of SMC and fibroblasts. Similarly, the administration of antioxidants blocks the generation of intracellular ROS, thereby inhibiting SMC and fibroblast proliferation and extracellular matrix synthesis. In addition to the prevention and treatment of vascular disease, such as atherosclerosis, graft disease, and restenosis, NAD(P)H oxidase inhibitors and antioxidants may be useful for the prevention and treatment of other conditions by decreasing cell proliferation and extracellular matrix synthesis associated therewith. These conditions include arthritis, keloid formation, cancer, tissue and organ fibrosis, and complications related to organ transplantation, metabolic syndrome, and radiation therapy.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-2005182020-A1
优先权日:2003-11-14
标题 :Ceramide de novo synthesis-based therapeutic and prophylactic methods, and related articles of manufacture
发明人：WORGALL TILLA S; DECKELBAUM RICHARD J
摘要:Described is a method for decreasing the amount of mSREBP in a cell characterized by an elevated level of mSREBP comprising contacting the cell with an agent that specifically inhibits de novo synthesis of ceramide in the cell, thereby decreasing the amount of mSREBP in the cell. Also described are related methods and articles of manufacture.